What's Going On in the World of GLP-1: What Athletes Need to Know

GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound — have become impossible to ignore. They've moved from specialty diabetes clinics to mainstream conversation faster than almost any drug class in recent memory. The weight loss results are real. The prescriptions are surging. And for a lot of people who train regularly, a reasonable set of questions is going unanswered in most of the coverage: What happens to your muscle mass? How should you be training? Does your nutrition strategy need to change?

This piece doesn't take a position on whether GLP-1 medications are right for you — that's a conversation between you and your doctor. What it does is lay out the fitness-specific picture as clearly as the current evidence allows.

What GLP-1 Drugs Actually Are

GLP-1 stands for glucagon-like peptide-1, a hormone produced naturally in the gut in response to eating. It signals the pancreas to release insulin, slows gastric emptying so food moves through the stomach more gradually, and sends satiety signals to the brain that reduce appetite. GLP-1 receptor agonists are drugs that mimic or amplify this hormone's effects.

They were originally developed for type 2 diabetes management — improving insulin sensitivity and blood glucose control — and the weight loss that accompanied them was initially considered a beneficial side effect. As higher-dose formulations were studied specifically for obesity, the weight loss outcomes proved significant enough to drive a new wave of prescriptions targeting body composition directly.

A few things worth clarifying about how these drugs work:

• They are not stimulants. They don't increase energy expenditure or elevate heart rate. The weight loss mechanism is almost entirely appetite suppression and reduced caloric intake.
• They are not a passive fix. The research is consistent: people who pair GLP-1 medications with lifestyle changes — including exercise and dietary improvements — achieve significantly better outcomes than those who rely on the medication alone.
• They work through a real physiological mechanism. The reduced appetite these drugs produce isn't willpower. It's a hormonal signal. Understanding that distinction matters for how you approach nutrition on them.

The drugs in this class differ in their targets and delivery — semaglutide (Ozempic/Wegovy) acts on GLP-1 receptors specifically; tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors — but from a training and nutrition standpoint, the practical implications are similar enough to address together.

The Muscle Question

This is the real concern for anyone who trains seriously. Rapid weight loss — from any cause — doesn't come exclusively from fat. A meaningful portion comes from lean mass, including muscle. The body, under a significant caloric deficit, doesn't carefully select only fat stores for fuel.

The data on GLP-1 medications is consistent on this point. Studies examining body composition changes during semaglutide treatment have found that somewhere between 25% and 40% of total weight lost can be lean mass in the absence of intentional muscle preservation strategies. For someone losing 30 pounds, that could mean 8–12 pounds of that comes from muscle rather than fat — a significant body composition outcome that isn't reflected in the headline weight loss number.

This isn't unique to GLP-1 drugs. The same pattern appears with any aggressive caloric restriction. What makes GLP-1 medications notable is that the rate of weight loss can be faster than what most people achieve through diet alone, which can accelerate the timeline on muscle loss if nothing is done to counteract it.

The intervention is the same one it has always been: resistance training and adequate protein intake. These two factors are the primary determinants of whether weight loss preserves or sacrifices lean mass. There is no metabolic shortcut around them. The medication changes the appetite equation; it doesn't change the muscle physiology.

How to Train on GLP-1s

Lower caloric intake means lower energy availability. This has real, practical implications for training — not reasons to avoid it, but reasons to approach it thoughtfully.

Prioritize Resistance Work

If you're going to make one change to your training on GLP-1 medications, let it be this: make sure you're lifting heavy and doing it consistently. Resistance training is the primary signal that tells the body to preserve muscle during a caloric deficit. A training program that is exclusively or predominantly cardio-based during a GLP-1 weight loss phase is one that increases the risk of significant muscle loss alongside fat loss. That's not a theoretical risk — it's what the body does when there's no mechanical reason to maintain the muscle.

This doesn't mean cardio is harmful. It means the priority order matters. Strength and resistance training should anchor your program, with conditioning work layered on top of it.

Expect Energy to Be Different

Reduced caloric intake affects training performance, particularly in workouts that rely on glycogen — high-intensity, high-rep, metabolic conditioning-style training. You may notice that your capacity for sustained high-intensity effort is lower than usual, especially early in a GLP-1 treatment period when the caloric reduction is most significant.

This is not a sign that something is wrong. It's a predictable adaptation to lower fuel availability. Intensity may need to scale back during this period. Pushing through severe fatigue or dizziness in training isn't a virtue — it's a liability. Listening to how the body is responding day to day matters more here than hitting arbitrary intensity targets.

Allow for Longer Recovery Windows

Recovery is partly a nutritional process. Muscle protein synthesis, glycogen replenishment, and tissue repair all require adequate substrate. In a significant caloric deficit, these processes compete with the body's other energy needs. Recovery may take longer than you're used to. Building in additional rest days, especially during the early months of treatment, is a reasonable and evidence-aligned adjustment — not a concession.

Protein and Nutrition

Protein targets matter more during GLP-1 treatment than at almost any other time. The general recommendation for active individuals trying to preserve muscle during weight loss is 0.7 to 1 gram of protein per pound of bodyweight per day. On GLP-1 medications, hitting that target becomes simultaneously more important and more difficult.

More important because the rate of potential lean mass loss is higher. More difficult because these drugs are specifically designed to suppress appetite — and protein-rich foods (meat, eggs, fish, legumes) tend to be filling. The combination of a suppressed appetite and high protein requirements is a real nutritional challenge that many people on GLP-1 medications underestimate until they start tracking.

Practical Strategies

• Protein first at every meal. When appetite is suppressed, you will run out of hunger before you run out of plate. Eat protein before anything else so that when satiety kicks in, you've already hit the most important nutritional target.
• Use shakes as a supplement, not a staple. Protein shakes are an efficient way to close a gap between what you've eaten and what you need. They shouldn't replace whole-food protein sources, but they're a practical tool when appetite is low and the alternative is simply not eating enough.
• Don't let low appetite become low protein. This is the specific failure mode to watch. The reduced overall caloric intake that GLP-1 medications produce is intentional. Allowing that to translate into protein deficiency is not — it's an unintended consequence that requires active management.
• Track, at least initially. You don't have to count macros indefinitely, but during the early months of GLP-1 treatment, a few weeks of tracking protein intake specifically will reveal whether you're hitting your targets or not. Most people are surprised by how low their intake is when appetite is suppressed.

What the Research Is Still Figuring Out

GLP-1 medications are relatively new at the scale and duration they're now being prescribed, and the long-term data simply doesn't exist yet. A few areas where the picture is incomplete:

Bone Density

Several studies have flagged potential decreases in bone mineral density associated with significant weight loss on GLP-1 medications. Weight-bearing exercise — including resistance training — is one of the primary stimuli for maintaining bone density, which reinforces the case for keeping that training in place during treatment. This is an active area of research, and the long-term implications aren't yet fully understood.

Muscle Fiber Composition

Whether GLP-1-driven weight loss disproportionately affects certain types of muscle fiber, or changes the ratio of fast-twitch to slow-twitch muscle in ways that matter for athletic performance, is not yet well characterized. The existing research on body composition largely measures total lean mass rather than fiber-specific changes.

Metabolic Adaptation

Significant caloric restriction — whether driven by medication or willpower — tends to produce metabolic adaptation, where the body reduces its resting energy expenditure over time. How GLP-1 medications interact with this process over multi-year treatment periods is still being studied. What happens to metabolic rate when medications are discontinued is another open question that the 10-year data doesn't yet exist to answer.

None of this is a reason to avoid these medications if your physician recommends them. It's a reason to stay engaged with the research as it develops, and to make decisions in partnership with someone who can monitor the relevant markers over time.